SEC Form 4 · accession 0000886163-15-000095
LIGAND PHARMACEUTICALS INC · LGND
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew E Korenberg
Officer — VP, Finance and CFO
Period of report
Aug 6, 2015
Accepted (ET)
Aug 7, 2015 · 4:23 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000886163
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 6, 2015 | A | 6,000 | $0.00 | A | 6,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $104.59 | Aug 6, 2015 | A | 25,000 | A | — | Aug 6, 2025 | Common Stock | 25,000 | 25,000 | D |
Explanation of responses
- F1Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 25% after one year, then 1/36th of the Optioned Shares per month thereafter.